JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G; The New England Journal Of Medicine, 2012, vol. 366, issue 9, p 787, ISSN 15334406. ISBN 15334406.
Full Text Resources Located for this Citation